BTIG analyst Mark Massaro notes that earlier today, a short report was published on GeneDx (WGS), which alleges wholesale reimbursement fraud ...
Das GeneDx-Management bestätigte, dass das Unternehmen kein "Code Stacking" betreibt und angemessene CPT-Codes für Genom- und Exom-Tests abrechnet, die das Kerngeschäft darstellen. Die Analysten hoben ...
BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...
TD Cowen analyst Daniel Brennan maintained a Buy rating on GeneDx Holdings (WGS – Research Report) today and set a price target of $118.00. The ...
Eine Analyse von InvestingPro zeigt, dass das Unternehmen mit einem gesunden Verhältnis von kurzfristigen Vermögenswerten zu kurzfristigen Verbindlichkeiten von 2,41 eine starke Fähigkeit zur ...
Adds analyst comment. GeneDX (NASDAQ:WGS) fell 4% after a short report from Grizzly Research on the genetic testing company. Grizzly Research disclosed that it's short shares of GeneDX (NASDAQ:WGS).
GeneDx Holdings Corp. (NASDAQ:WGSWW – Get Free Report) was the target of a large drop in short interest in January.As of January 15th, there was short interest totalling 7,800 shares, a drop of ...
Shares of WGS opened at $74.85 on Friday. GeneDx Holdings Corp. has a twelve month low of $3.62 and a twelve month high of $98.87. The company has a market capitalization of $2.06 billion, a P/E ...
GAITHERSBURG, Md., January 28, 2025--GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025 STAMFORD, Conn., January 17, 2025--GeneDx Holdings Corp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback